ORMP
Oramed Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$3.41
+0.17 (+5.25%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.69M | 32.28M | 32.90M |
| Net Income | 6.94M | 5.51M | 7.09M |
| EPS | — | — | — |
| Profit Margin | 21.2% | 17.1% | 21.6% |
| Rev Growth | +22.5% | +15.3% | -1.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 14.94M | 16.15M | 14.75M |
| Total Equity | 98.42M | 85.85M | 90.16M |
| D/E Ratio | 0.15 | 0.19 | 0.16 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 9.65M | 8.62M | 9.08M |
| Free Cash Flow | 3.16M | 3.23M | 4.24M |